Cargando…
The Combination of Immunosuppression and Carrier Cells Significantly Enhances the Efficacy of Oncolytic Poxvirus in the Pre-Immunized Host
Pre-existing anti-poxvirus immunity in cancer patients presents a severe barrier to poxvirus-mediated oncolytic virotherapy. We have explored strategies of immunosuppression (IS) and/or immune evasion for efficient delivery of an oncolytic vaccinia virus (vvDD) to tumors in the pre-immunized mice. T...
Autores principales: | Guo, Z. Sheng, Parimi, Vamsi, O'Malley, Mark E., Thirunavukarasu, Pragatheeshwar, Sathaiah, Magesh, Austin, Frances, Bartlett, David L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2982886/ https://www.ncbi.nlm.nih.gov/pubmed/20703311 http://dx.doi.org/10.1038/gt.2010.104 |
Ejemplares similares
-
Oncolytic Poxvirus Armed with Fas Ligand Leads to Induction of Cellular Fas Receptor and Selective Viral Replication in FasR Negative Cancer
por: Sathaiah, Magesh, et al.
Publicado: (2011) -
TRAIL Gene-Armed Oncolytic Poxvirus and Oxaliplatin Can Work Synergistically against Colorectal Cancer
por: Ziauddin, Mohammed F, et al.
Publicado: (2010) -
Rapid Generation of Multiple Loci-Engineered Marker-free Poxvirus and Characterization of a Clinical-Grade Oncolytic Vaccinia Virus
por: Guo, Zong Sheng, et al.
Publicado: (2017) -
Oncolytic viruses as therapeutic cancer vaccines
por: Bartlett, David L, et al.
Publicado: (2013) -
A cautionary note on the selectivity of oncolytic poxviruses
por: Tang, Bingtao, et al.
Publicado: (2019)